Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer
2021 | journal article
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer
Mountzios, G.; Samantas, E.; Senghas, K.; Zervas, E.; Krisam, J.; Samitas, K. & Bozorgmehr, F. et al. (2021)
ESMO Open, 6(5) art. 100254. DOI: https://doi.org/10.1016/j.esmoop.2021.100254
Documents & Media
Details
- Authors
- Mountzios, G.; Samantas, E.; Senghas, K.; Zervas, E.; Krisam, J.; Samitas, K.; Bozorgmehr, F.; Kuon, J.; Agelaki, S.; Baka, S.; Athanasiadis, I.; Gaissmaier, L.; Elshiaty, M.; Daniello, L.; Christopoulou, A.; Pentheroudakis, G.; Lianos, E.; Linardou, H.; Kriegsmann, K.; Kosmidis, P.; El Shafie, Rami ; Kriegsmann, M.; Psyrri, A.; Andreadis, C.; Fountzilas, E.; Heussel, C.-P.; Herth, F. J.; Winter, H.; Emmanouilides, C.; Oikonomopoulos, G.; Meister, M.; Muley, T.; Bischoff, H.; Saridaki, Z.; Razis, E.; Perdikouri, E.-I.; Stenzinger, A.; Boukovinas, I.; Reck, M.; Syrigos, K.; Thomas, M.; Christopoulos, P.
- Abstract
- The advanced lung cancer inflammation index [ALI: body mass index × serum albumin/neutrophil-to-lymphocyte ratio (NLR)] reflects systemic host inflammation, and is easily reproducible. We hypothesized that ALI could assist guidance of non-small-cell lung cancer (NSCLC) treatment with immune checkpoint inhibitors (ICIs).
- Issue Date
- 2021
- Journal
- ESMO Open
- eISSN
- 2059-7029
- Language
- English
